Urogenital Atrophy (Genitourinary Syndrome of Menopause) - Symptoms, Causes, Treatment & Prevention

Overview

Urogenital atrophy, now more commonly called **Genitourinary Syndrome of Menopause (GSM)**, is a collection of symptoms that arise from the thinning, drying, and inflammation of the vulvovaginal and lower urinary tract tissues after the decline of estrogen that occurs with menopause. While the term “menopause” suggests an age‑related change, GSM can also affect younger women who have had surgical menopause (bilateral oophorectomy), those on long‑term ovarian suppression, or women with premature ovarian insufficiency.

**Who it affects:** Approximately 40%–50% of post‑menopausal women experience at least one symptom of GSM, and up to 20% report that it significantly impacts quality of life ^{[1] Mayo Clinic}. The condition is under‑reported because many women consider the symptoms “normal” aging and do not seek care.

**Prevalence by age:**

• Women aged 45‑55 years: ~30% report vaginal dryness or irritation.
• Women aged 55‑65 years: ~45% report GSM symptoms.
• Women >65 years: >60% may have one or more signs of urogenital atrophy.

Symptoms

GSM can involve the vulva, vagina, urethra, bladder, and even the lower urinary tract. Symptoms often appear gradually and may be intermittent.

Vulvar & Vaginal Symptoms

• Vaginal dryness – a sensation of cotton‑like or gritty tissue, often worsening during intercourse.
• Itching or burning – especially after sexual activity or during urination.
• Vaginal irritation or soreness – may be mistaken for infection.
• Dyspareunia (painful intercourse) – can be superficial (entry pain) or deep.
• Vaginal spotting or bleeding after intercourse due to fragile mucosa.
• Loss of elasticity – thinner, less lubricated vaginal walls.
• Recurrent urinary tract infections (UTIs) – altered flora from low estrogen.

Urinary Symptoms

• Urgency – sudden need to void.
• Frequency – needing to urinate more than 8 times per day.
• Nocturia – waking 2+ times nightly to urinate.
• Dysuria – burning or pain during voiding.
• Stress urinary incontinence – leakage with coughing, sneezing, or exercise.
• Urinary incontinence associated with urgency (UUI).

Other Possible Manifestations

• Reduced sexual satisfaction or desire due to discomfort.
• Psychological impact: embarrassment, anxiety, or depression.
• Secondary infections (e.g., bacterial vaginosis) from altered pH.

Causes and Risk Factors

GSM is primarily driven by the **decline in circulating estrogen** that leads to structural and functional changes in the genitourinary tissues.

Physiologic Causes

• Estrogen deficiency – Reduced estrogen results in decreased collagen, elastin, and glycogen production, leading to thinner epithelium and less moisture.
• Reduced blood flow – Vasoconstriction worsens tissue hypoxia.
• Altered microbiome – Lactobacilli, which thrive on estrogen‑dependent glycogen, decline, allowing pathogenic bacteria to proliferate.

Risk Factors

• Natural menopause (average onset 51 years).
• Surgical menopause (bilateral oophorectomy) – symptoms may start within weeks.
• Long‑term use of anti‑estrogen therapies (e.g., tamoxifen, aromatase inhibitors).
• GnRH agonists for endometriosis or fertility preservation.
• Smoking – accelerates tissue aging and reduces blood flow.
• Diabetes mellitus – impaired microcirculation and increased infection risk.
• Chronic use of vaginal douches, harsh soaps, or scented products that disrupt the natural flora.

Diagnosis

Diagnosing GSM involves a combination of patient‑reported symptoms, clinical examination, and occasionally targeted tests. The goal is to confirm estrogen‑related atrophy and rule out infection, malignancy, or other dermatologic conditions.

Clinical Evaluation

• Medical history – Menopausal status, sexual activity, urinary symptoms, medication list.
• Physical exam – Visual inspection of vulva and vagina, often with a speculum to assess mucosal color, dryness, petechiae, or atrophic changes.
• Pelvic exam – Evaluation of pelvic floor tone and urinary leakage.

Laboratory & Instrumental Tests (when indicated)

• Vaginal pH measurement – A pH > 5 suggests atrophy (normal < 4.5).
• Microscopy of vaginal secretions – To exclude infection (e.g., bacterial vaginosis, yeast).
• Urinalysis & urine culture – If recurrent UTIs are suspected.
• Pelvic ultrasound – Rarely needed, but can evaluate bladder wall thickness or rule out masses.
• Biopsy – Only if suspicious lesions or unexplained bleeding are present.

Treatment Options

Therapy is individualized, focusing on symptom severity, personal preferences, and contraindications. Treatment categories include topical estrogen, non‑hormonal agents, systemic hormone therapy, and lifestyle modifications.

Topical (Local) Estrogen Therapies

• Vaginal estrogen creams (e.g., estradiol 0.01%) – Applied 2–3 times/week initially, then maintenance 1–2 times/week. Effective for dryness, dyspareunia, and urinary symptoms.
• Vaginal tablets (e.g., estradiol 10 µg) – Inserted nightly for 2 weeks, then twice weekly.
• Vaginal rings (e.g., estradiol 7.5 µg/day) – Continuous low‑dose release for up to 3 months; replaced quarterly.
• Benefits: minimal systemic absorption (< 2% of oral dose), rapid symptom relief within 2–4 weeks. Contra‑indicated in estrogen‑dependent cancers or active thromboembolic disease.

Systemic Hormone Therapy (HT)

For women who also have vasomotor symptoms (hot flashes) or bone loss, systemic HT (oral, transdermal, or injectable) may be considered. The estrogen component helps GSM, while the progestogen protects the endometrium in women with a uterus.

Non‑Hormonal Options

• Moisturizers & lubricants – Over‑the‑counter (OTC) products containing water‑based, silicone‑based, or hyaluronic‑acid formulations; used daily for moisture and acutely before intercourse.
• Vaginal dehydroepiandrosterone (DHEA) – prasterone 6.5 mg – Converted locally to estrogen and androgen; FDA‑approved for dyspareunia.
• Selective estrogen receptor modulators (SERMs) – Ospemifene 60 mg daily improves vaginal dryness and dyspareunia without uterine stimulation.
• Laser & radiofrequency therapies – Fractional CO₂ or erbium‑YAG laser (e.g., MonaLisa Touch) promote collagen remodeling; evidence is mixed, and FDA does not yet approve for GSM, so discuss risks/benefits.

Lifestyle & Adjunctive Measures

• Regular pelvic floor exercises (Kegels) – Improves urinary continence.
• Stopping smoking and limiting alcohol reduces vascular compromise.
• Avoiding irritants: scented soaps, douches, and tight synthetic underwear.
• Maintaining adequate hydration (≥ 2 L water/day) helps mucosal moisture.

Living with Urogenital Atrophy (Genitourinary Syndrome of Menopause)

GSM is chronic but manageable. Below are practical daily‑life tips.

Sexual Health

• Use a **water‑based lubricant** before intercourse; reapply as needed.
• Consider **vaginal moisturizers** (applied 2–3 times weekly) to maintain baseline hydration.
• Communicate openly with your partner; foreplay that includes gentle stimulation can increase natural lubrication.

Urinary Comfort

• Timed voiding (every 2–3 hours) can reduce urgency.
• Practice the “double‑void” technique: urinate, wait a few seconds, then try again.
• Wear breathable cotton underwear and avoid prolonged damp clothing.

Skincare of the Vulvovaginal Area

• Wash with lukewarm water only; pat dry gently.
• Apply a **fragrance‑free barrier cream** (e.g., plain petroleum jelly) after bathing if skin feels tight.

Monitoring & Follow‑Up

• Schedule a follow‑up with your clinician 4–6 weeks after initiating any new therapy to assess response and side effects.
• Keep a symptom diary (dryness, pain, urinary frequency) to discuss trends.

Prevention

While menopause is inevitable for most women, certain actions can delay or lessen the severity of GSM.

• Maintain regular physical activity – Improves circulation and pelvic floor strength.
• Balanced diet rich in phytoestrogens (soy, flaxseed, legumes) may modestly support estrogenic activity ^{[2] NIH}.
• Quit smoking – Reduces vascular damage and tissue atrophy.
• Early discussion of hormone therapy with a healthcare provider if you anticipate premature menopause.
• Use mild, pH‑balanced cleansers to protect the natural microbiome.

Complications

If GSM remains untreated, several complications may arise:

• Recurrent urinary tract infections – up to 30% higher risk in untreated GSM ^{[3] CDC}.
• Urinary incontinence progression – irritative symptoms can worsen to mixed incontinence.
• Sexual dysfunction – chronic dyspareunia can lead to avoidance of intimacy, affecting relationships and mental health.
• Vulvar or vaginal ulceration – severe atrophy may cause fissures or bleeding.
• Pelvic organ prolapse – weakened support structures may be exacerbated by chronic coughing, constipation, or heavy lifting.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Genitourinary syndrome of menopause (GSM).” Updated 2023. https://www.mayoclinic.org
2. National Institutes of Health. “Dietary Phytoestrogens and Menopausal Health.” 2022. https://www.nih.gov
3. Centers for Disease Control and Prevention. “Urinary Tract Infection (UTI) Guidelines.” 2021. https://www.cdc.gov
4. American College of Obstetricians and Gynecologists (ACOG). “Management of Menopausal Symptoms.” Practice Bulletin No. 141, 2020.
5. Cleveland Clinic. “Genitourinary Syndrome of Menopause (GSM).” 2023. https://my.clevelandclinic.org